Back
Compare AU
Compare DRUG vs. CETF
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the VanEck FTSE China A50 ETF (CETF). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | CETF | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 72 | 39 |
Median incremental investment | $740.50 | $1,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,980.16 | $1,064.37 |
Average age group | > 35 | > 35 |
Key Summary
DRUG | CETF | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | CETF.AX was created on 2015-06-26 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund seeks to provide investors with access to a portfolio of the 50 largest companies in the mainland Chinese market. |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) BRL - BRAZILIAN REAL (0 %) | Contemporary Amperex Technology Co Ltd Class A (8.34 %) Kweichow Moutai Co Ltd Class A (8.14 %) Zhongji Innolight Co Ltd Class A (4.88 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Financials (34.11 %) Consumer Staples (28.51 %) Other (22.20 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | China (98.90 %) Hong Kong (0.94 %) United States (0.16 %) |
Management fee | 0.57 % | 0.6 % |
Key Summary
DRUG | CETF | |
|---|---|---|
Issuer | BetaShares | VanEck |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | FTSE China A50 Index - CNY |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.6 % |
Price | $8.84 | $62.61 |
Size | $174.658 million | $33.990 million |
10Y return | 78.23 % | 18.87 % |
Annual distribution yield (5Y) | 1.82 % | 2.03 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 26/06/2015 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | CETF | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 72 | 39 |
Median incremental investment | $740.50 | $1,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,980.16 | $1,064.37 |
Average age group | > 35 | > 35 |
Pros and Cons
DRUG | CETF | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | CETF |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |